---
title: "CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296243257.md"
description: "CARsgen Therapeutics reported FY26 H1 revenue of RMB 61.92 million, a 21.49% increase driven by zevor-cel sales. The net loss narrowed to RMB 70.84 million, while adjusted non-IFRS net loss improved to RMB 32 million. Cash reserves rose to RMB 1.4 billion following a capital raise. Additionally, the NMPA cleared satri-cel for gastric cancer treatment, and the company received 110 orders for zevor-cel from Huadong Medicine."
datetime: "2026-08-18T14:28:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296243257.md)
  - [en](https://longbridge.com/en/news/296243257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296243257.md)
generator: "portal-rs"
---

# CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million

-   CARsgen posted revenue of RMB 62 million, up 21.58% year over year, driven mainly by zevor-cel sales volume growth. \* Net loss narrowed to RMB 71 million from a year earlier, helped by higher gross profit; selling and distribution expenses rose to RMB 12 million. \* Adjusted net loss (non-IFRS) improved to RMB 32 million, as share-based compensation climbed to RMB 39 million. \* Cash and cash equivalents rose to RMB 1.4 billion, up RMB 277 million since Dec. 31, on RMB 405 million top-up placing proceeds. \* NMPA cleared satri-cel for Claudin18.2-positive advanced gastric or gastroesophageal junction cancer in June; 110 zevor-cel orders received from Huadong Medicine. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260818-12289478), on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02171.HK](https://longbridge.com/en/quote/02171.HK.md)
- [000963.CN](https://longbridge.com/en/quote/000963.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [World’s First Solid-Tumor CAR-T Therapy Begins Rollout in China With First Foreign Patient](https://longbridge.com/en/news/296349187.md)
- [CARsgen says satri-cel gastric cancer consolidation trial shows no recurrences to date](https://longbridge.com/en/news/292686238.md)
- [Yeebo appoints John Chan as executive director after Leung retirement](https://longbridge.com/en/news/296797184.md)
- [Buy Bitcoin, Not This Surging Crypto Stock: Cramer](https://longbridge.com/en/news/296617504.md)
- [AIM Vaccine files NMPA registration for high-potency human diploid rabies vaccine](https://longbridge.com/en/news/296714865.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**